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Abstract
Background: Activated leukocyte cell adhesion molecule (ALCAM) is implicated in the prognosis of multiple
cancers with low level expression associated with metastasis and early death in breast cancer. Despite this
significance, mechanisms that regulate ALCAM gene expression and ALCAM’s role in adhesion of pre-metastatic
circulating tumor cells have not been defined. We studied ALCAM expression in 20 tumor cell lines by real-time
PCR, western blot and immunochemistry. Epigenetic alterations of the ALCAM promoter were assessed using
methylation-specific PCR and bisulfite sequencing. ALCAM’s role in adhesion of tumor cells to the vascular wall was
studied in isolated perfused lungs.
Results: A common site for transcription initiation of the ALCAM gene was identified and the ALCAM promoter
sequenced. The promoter contains multiple cis-active elements including a functional p65 NF-B motif, and it
harbors an extensive array of CpG residues highly methylated exclusively in ALCAM-negative tumor cells. These
CpG residues were modestly demethylated after 5-aza-2-deoxycytidine treatment. Restoration of high-level ALCAM
expression using an ALCAM cDNA increased clustering of MDA-MB-435 tumor cells perfused through the
pulmonary vasculature of ventilated rat lungs. Anti-ALCAM antibodies reduced the number of intravascular tumor
cell clusters.
Conclusion: Our data suggests that loss of ALCAM expression, due in part to DNA methylation of extensive
segments of the promoter, significantly impairs the ability of circulating tumor cells to adhere to each other, and
may therefore promote metastasis. These findings offer insight into the mechanisms for down-regulation of
ALCAM gene expression in tumor cells, and for the positive prognostic value of high-level ALCAM in breast cancer.
Background
ALCAM/CD166 is an immunoglobulin cell adhesion
molecule expressed by neuronal, endothelial, hemato-
poietic and epithelial cells [1-13]. It’s up-regulation in
cancer was first identified at the RNA level in melanoma
cell lines as memD [14]. Subsequently, increased
ALCAM expression was found in melanoma tumors in
situ [13,15]. More widespread deregulation of ALCAM
expression has since been reported in several other
tumors including those of the prostate [16,17],
esophagus [18], colon [19], bladder [20] and pancreas
[21]. Alterations in ALCAM ex p r e s s i o ni nt u m o r sh a v e
recently been reviewed by Ofori-Acquah and King [22].
In a study of primary breast cancer tissues and non-
neoplastic mammary tissue from the same mastec-
tomies, we discovered that the level of ALCAM tran-
scripts was lower in breast cancer tissues from patients
who had metastases to regional lymph nodes [23], and
that primary tumors from patients who died of breast
cancer had significantly lower levels of ALCAM tran-
scripts [23]. Subsequent studies showed that patients
with the lowest level of ALCAM transcripts develop ske-
letal metastasis [24], that low ALCAM correlated with
an aggressive tumor phenotype and significantly nega-
tive correlation between ALCAM expression and tumor
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ALCAM in breast cancer tissues has emerged as a pre-
dictor of good outcome among patients treated with
tamoxifen [26] and adjuvant chemotherapy [27,28].
Tumor cells circulate in blood as single entities and
multi-cellular emboli [29], and form secondary colonies
in the vascular wall. This mechanism of metastasis is
supported by evidence showing that tumor cells per-
fused in isolated rat lungs attach to the endothelia wall
with minimum extravasation, leaving the endothelium-
attached cells as the seeds of secondary tumors [30].
Indeed, in primary tumors derived from subcutaneous
injection of murine breast carcinoma cells in immuno-
compromised mice, early metastatic colonies are intra-
vascular in origin [31]. That adhesion molecules
tethered on tumor cell surfaces influence their coloniza-
tion of the lung, and downstream metastatic processes,
is supported by the finding that the loss of ALCAM at
the cell surface confers a high risk for disease progres-
sion and mortality in nodal negative cases of breast can-
cer [26].
In this study, the ALCAM gene was cloned and func-
tionally characterized in a panel of breast cancer and
melanoma tumor cell lines, and the influence of
ALCAM on homotypic tumor cell adhesion in the pul-
monary vasculature investigated. Our findings provide
new mechanistic insights on ALCAM that can be devel-
oped further to alter its negative influence in tumor cell
progression.
Results
ALCAM expression in tumor cells
ALCAM mRNA is significantly reduced in primary
breast tumors from patients with metastatic disease
however the amount of ALCAM in breast cancer cells
at metastatic sites remains poorly understood. In this
study, ALCAM mRNA in sixteen breast cancer cell lines
derived from metastatic breast cancer tumors in the
brain, lymph node and the pleural cavity, and primary
breast tumors in ductal epithelium were quantified by
qRT-PCR. Most cell lines derived from pleural effusions
(MB-157, MDA-MB-435, HCC1428, MDA-MB-453,
MCF-7, MDA-MB-231 and SK-BR-3) expressed rela-
tively low levels of ALCAM mRNA, while cells originat-
ing from the lymph node (HCC70, HCC1008 and
BT549) expressed relatively high amounts of ALCAM
mRNA (Fig. 1A). ALCAM mRNA was virtually not
detectable in MDA-MB-435. Regarding melanoma,
ALCAM mRNA was markedly elevated in most of the
cell lines (LOX, C8161.9, MelJuso) in agreement with
the increased expression in primary tumors (Fig. 1A).
Figure 1B shows that ALCAM protein levels determined
by western blot analysis showed good correlation with
ALCAM mRNA in most tumor cells. Most notably we
did not detect ALCAM protein in MDA-MB-435 and
FEMX-I tumor cells (Fig. 1B). ALCAM was generally
expressed at cell-cell contacts of confluent tumor cell
cultures although cytoplasmic localization was also
detected (Fig. 1C). These data indicate that ALCAM is
variably expressed in breast cancer cell lines, with the
lowest level of expression, predominantly in cells derived
from distant metastatic sites.
Structure of the ALCAM promoter and mRNA synthesis at
the ALCAM gene locus
The human ALCAM gene is located on the long arm of
chromosome 3 [2], therefore we designed primers com-
plimentary to a genomic clone of human chromosome 3
to amplify and sequence 1000 base pairs of a putative
ALCAM promoter. Comparing this sequence with
entries in the GenBank database identified several refer-
ence clones with complete identity to our clone, except
for variations of two nucleotides at -154 (A/G) and -618
(C/T) (data not shown). Signal scan analysis revealed
that 1 Kb ALCAM promoter contained one copy of a
direct repeat, ATTATTATTA sequence, present in the
Drosophila melanogaster genes encoding transcription
factor IIB (TFIIB) and the TATA-box-binding protein
(TBP) and no canonical TATA-box.
To identify the site of transcription initiation on the
ALCAM gene, complimentary DNA (cDNA) was pre-
pared from non-malignant human cell lines (MCF-12A)
and amplified in two sequential PCR analyses using
ALCAM-specific reverse primers, and 5’RACE forward
primers (Fig. 2A). A single major band of approximately
400 bp was identified in the final nested PCR experi-
ments (Fig. 2B, lane 3). This product was cloned into T-
vectors and 20 clones isolated and sequenced. The
sequencing data revealed the presence of four putative
transcription start sites, located 500, 496, 379 and 349
upstream of the ALCAM translation start site (Fig. 2C).
These putative transcriptional start sites had variable
agreement with the initiator consensus PyPyA+1NT/
ApyPy (where Py is pyrimidine), and RNA synthesis
usually begins at the adenine (+1). The site at -349
(CCAATA) most closely matched the initiator consen-
s u s ,w i t hac o r es e q u e n c e[ C A N T ]f o rs t r o n gi n i t i a t i o n ,
with a T at +3 and A at +1, and surrounded by pyrimi-
dines except at position +4. Clones with this site of
initiation were the most abundant (65%) identified in
our 5’RACE experiments.
Functional analysis of the ALCAM promoter in tumor cells
Preliminary studies showed that DNA sequences
upstream of -650 of the ALCAM gene drove expression
of a promoter-less luciferase gene in a wide variety of
cell types, and that this activity required an intact Sp1
element at -550 (data not shown). Transient activities of
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Page 2 of 16constructs p650, p800, p1000 and p1200 ALCAMLuc
were virtually identical. Activity of p1200ALCAMLuc
was 2-3-fold higher than of p1000ALCAMLuc (Fig. 3A)
in three melanoma cell lines (C8161.9, LOX and Mel-
juso), which suggested thep r e s e n c eo fap o s i t i v ecis-
acting element within the sequence between -1200 to
-1000. A putative NF-B sequence was identified at
-1140, this motif was mutated using site-directed muta-
genesis (GGGGTTGCCC®GGAATTGCCC) to investi-
gate its role in ALCAM promoter activity. This
Figure 1 ALCAM expression in tumor cells. A) Quantification of ALCAM mRNA by qRT-PCR. Data shown for each cell line is the mean of three
analyses each in triplicate. B) Western blot analysis of ALCAM protein in the indicated cells lines. Whole cell lysates (20 μg) were probed with anti-
ALCAM antibody, and the filter stripped and re-probed for a-tubulin. C) Immunocytochemical analysis for ALCAM expression and sub-cellular
localization in breast cancer cell lines HCC1806 and HCC1500. Cells were stained for ALCAM (red) and nucleus (blue) using the DAPI reagent.
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level found in the p1000 construct (Fig. 3B). We pre-
sumed that NF-B bound to this cognate element in the
ALCAM promoter, and tested this hypothesis using a
complement of in vitro and in vivo DNA-protein assays.
LOX cell nuclear extracts formed three unique com-
plexes (B1, B2 and B3) of variable intensities with a bio-
tin-labeled -1140 ALCAM NF-B probe (Fig. 4A (i),
lane 2). Competition with a 50-fold molar excess of
unlabeled wild-type probe abolished assembly of com-
plex B2 and B3 (lane 3), while an unlabeled mutant
probe with a 2-bp substitution of the NF-Bc o n s e n s u s
sequence (GGGGTTGCCC®GGAATTGCCC) had neg-
ligible or reduced impact on B2 and B3 complex forma-
tion (lane 4). Anti-p65 antibody markedly reduced the
intensity of complex B2 (lane 5), and B3 to a moderate
extent. CHIP analysis using anti-p65 antibodies con-
firmed occupancy of p65 on the endogenous ALCAM
Figure 2 Transcription initiation sites in the ALCAM gene. A) Schematic diagram of the 5’RACE approach. Positions of primers AL1, AL2 and
AL3 are shown. B) Ethidium bromide stained agarose gel showing DNA marker (lane 1), and products of 5’RACE reaction using primers AAP and
AL2 (lane 2), UAP and AL3 (lane 3). Lane 4 is negative PCR control (BL). C) Sequence of a 5’ UTR clone of ALCAM showing multiple sites of RNA
synthesis (arrows.) The most common site identified is shown underlined. Sequence of AL3 primer is double-underlined.
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Page 4 of 16promoter in all three melanoma cell lines (Fig. 4A (ii),
lanes 1-3). Collectively, these data show that protein
complexes containing the p65 NF-B subunit bind to a
cognate sequence at or around the -1140 element on
the human ALCAM promoter. To validate these binding
experiments, a DNA construct expressing NF-B
(pCMV-65) was used in co-trans-activation assays, and
this showed that co-transfection of 500 ng p1200
ALCAMLuc with 100 ng pCMV or pCMV-65 plasmid
DNA significantly increased ALCAM promoter activity
only in conjunction with the p65 expression vector (Fig.
4A (iii). We concluded from these data that NF-B acti-
vates the human ALCAM promoter.
Next, we assessed the activity of various ALCAM pro-
moter constructs truncated at -650, -800, -1000 and
-1200 in breast cancer cells, and discovered no appreci-
able activity, even though these same cells supported
high level activity of a CMV promoter driving a b-gal
reporter gene (data not shown). We presumed this was
likely due to the presence of negative regulatory ele-
ments and therefore assayed additional DNA constructs
truncated at -1400, -1800 and -2600. Activity of these
Figure 3 ALCAM promoter activity in melanoma tumor cells. A) Schematic diagram of DNA constructs used for reporter gene assays
depicting truncations of the ALCAM promoter cloned upstream of a promoter-less luciferase (Luc) gene. Histogram shows the relative luciferase
activity for each construct in melanoma cell lines. B) Schematic diagram as described above, and activity of the p1200ALCAMLuc construct
containing a wild-type (filled circle) or mutant (open circle) consensus binding sequence for NF-B in the ALCAM promoter.
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Page 5 of 16Figure 4 NF-B binding to the ALCAM promoter and activity of the ALCAM promoter in breast cancer cell lines. A) p65 binding and
trans-activation of the ALCAM promoter. (i) EMSA showing mobility of the -1140 NF-B probe in the absence of nuclear extract (lane 1).
Complexes B1, B2 and B3 form in the presence of LOX melanoma cell nuclear extracts (lane 2), subsequent lanes contain unlabelled wild-type
NF-B probe (lane 3), unlabelled mutant NF-B probe (lane 4) and anti-p65 antibody (lane 5). (ii) ChIP assay showing PCR products for the -1140
ALCAM NF-B motif and flanking DNA sequence amplified from chromatin of C8161.9 (lane1), LOX (lane 2) and Meljuso (lane3) cells precipitated
with anti-p65 antibodies. Absence of PCR product in immunoprecipitation with non-immune IgG (lane 4), lane 5 (input DNA). (iii) Activity of
p1200ALCAMLuc in C8161.9 and LOX cells over-expressing p65 or control vector. B) Schematic diagram of ALCAM reporter constructs and
histogram showing relative luciferase activity for each in breast cancer cells with high (HCC70, MDA-MB-231, T47D), medium (BT549, CAMA-1)
and low (HCC 1500, MCF-7,-SK-BR-3) ALCAM expression.
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Page 6 of 16larger promoter fragments remained relatively low in
breast cancer cells irrespective of the level of ALCAM
expression (Fig. 4B and data not shown).
DNA methylation silences ALCAM expression in tumor
cells
Results from our reporter gene assays highlighted epige-
netic modification as the basis for the lack of ALCAM
expression in the MDA-MB-435 cell line. This idea was
consistent with our sequencing data showing that the
ALCAM promoter is GC-rich, and regulated by Sp1
(data not shown). To investigate this idea, genomic
DNA from a large panel of breast cancer cells was mod-
ified by treatment with sodium bisulfite, and amplified
using primers that discriminate methylated and
unmethylated DNA (Fig. 5A). Unmethylated (U) DNA
was specifically amplified in all breast cancer cell lines
with detectable ALCAM expression, but not in the
MDA-MB-435 cell line, which lacks endogenous
ALCAM (Fig. 5A). Conversely, PCR product of methy-
lated (M) DNA was present only in reactions using
MDA-MB-435 DNA (Fig. 5A). Sequencing of bisulfite-
modified DNA revealed that virtually all CpG islands in
the proximal ALCAM promoter were methylated in
MDA-MB-435 tumor cells, with percentage methylation
ranging from 15% to 60% (Fig. 5B). A similarly high
degree of methylation was found in the FEMX-1 mela-
noma cell line (up to 75% of specific CpG residues),
which also lacks ALCAM expression while all other
tumor cells with appreciable ALCAM expression had a
negligible (0-5%) level of DNA methylation (Fig. 5B).
To directly confirm that CpG methylation silences the
ALCAM gene, MDA-MB-435 cells were treated with 5-
aza-2-deoxycytidine which reduced methylation at each
C p Gs i t eb y3t o3 7 %a tc o n c e n t r a t i o n so f5μMa n d1 0
μM of the drug (Fig. 6A and data not shown). This
modest degree of demethylation was accompanied by
significantly increased ALCAM expression at both
mRNA and protein levels in MDA-MB-435 cells (Fig.
6B). Collectively, these data identify CpG methylation of
the ALCAM promoter as one mechanism for controlling
ALCAM gene expression.
ALCAM clusters tumor cells perfusing through an isolated
rat lung
The isolated ventilated perfused rat lung system has pre-
viously been used to investigate the fate of circulating
tumor cells, and was employed here to test the influence
ALCAM has on these cells. Stable transfection of an
ALCAM-GFP construct conferred high level ALCAM
expression in MDA-MB-435 cells, and importantly loca-
lized ALCAM to sites of cell-cell contact in confluent cul-
tures (Fig. 7A). Perfusion of this clone into rat lungs
caused congestion of tumor cells in the pulmonary
vasculature, while relatively few cells were retained in
experiments using a control clone expressing an empty
vector (Fig. 7B). Quantitative analysis revealed more than
2-fold increase in the number of the ALCAM-positive
MDA-MB-435 cells retained in the rat lung (Fig. 7C),
compared to the ALCAM-negative variant. Pre-treating
ALCAM-positive MDA-MB-435 cells with anti-ALCAM
antibodies prior to perfusion significantly reduced the
number of tumor cells in the rat lung (Fig. 7C). Additional
control experiments showed that anti-ALCAM antibodies
did not alter the total number of ALCAM-negative MDA-
MB-435 tumor cells retained in the rat lung.
Anti-ALCAM antibody inhibits clustering of perfusing
tumor cells
Next, we focused on the mechanisms of retention of
tumor cells in the lung by counting the number of intra-
vascular tumor cell clusters and single tumor cells
adherent to endothelial walls. ALCAM expression
increased by 3-fold the number of MDA-MB-435 tumor
cell clusters, while anti-ALCAM antibody reduced this
number significantly (Fig. 7D). On the contrary,
ALCAM expression had no significant impact on the
number of single MDA-MB-435 tumor cells adhering to
the endothelial wall, and anti-ALCAM antibody did not
influence this number (Fig. 7E). These data indicate that
t h ep r e s e n c eo fA L C A Me n h a n c e sr e t e n t i o no ft u m o r
cells in the pulmonary vasculature primarily as clusters
of cells tightly adherent to each other, and not as indivi-
dual cells adherent to the endothelium. Recent findings
indicate that the parental MDA-MB-435 cell line is mel-
onocytic in origin and may therefore exhibit adhesive
behaviors atypical of breast cancer cells. To address this
concern and also confirm our findings in cells endogen-
ously expressing ALCAM, perfusion experiments were
performed using MDA-MB-231. These highly-expressing
ALCAM tumor cells formed several clusters while per-
fusing the pulmonary vasculature of the rat lung (Fig.
8A), two function blocking ALCAM antibodies consis-
tently reduced significantly the total number retained in
the rat lung, while IgG had no impact (Fig. 8B, C).
Discussion
Altered expression of the cell adhesion molecule
ALCAM is associated with progression, metastasis and
response to therapy in multiple cancers, yet specific
DNA elements that regulate ALCAM promoter activity
have not previously been defined. We found a consensus
NF-B element at -1140 and site-directed mutagenesis
of this element significantly reduced ALCAM promoter
activity. Over-expression of p65 NF-B increased
ALCAM promoter activity, while p65 occupied the cog-
nate motif on the endogenous ALCAM promoter in
melanoma cells lines (Fig. 4A ii). These data strongly
King et al. Molecular Cancer 2010, 9:266
http://www.molecular-cancer.com/content/9/1/266
Page 7 of 16Figure 5 Promoter methylation regulates ALCAM expression in tumor cells. A) Sequence of the proximal ALCAM promoter showing
multiple CpG islands (in bold) and methylation-specific primer targets (underlined). Ethidium bromide stained agarose gel showing PCR products
for unmethylated (U) and methylated (M) genomic DNA. B) CpG methylation profile of the ALCAM promoter in the interval -62 and -409 relative
to the cap site as determined by pyrosequencing for the indicated breast (MDA-MB-435, MCF-7, HCC-1428, HCC-1008) and melanoma (FEMX-1,
MelJuso, LOX, C8161.9) tumor cells. ALCAM protein detected by western blot analysis is shown for each cell line. Note that the maximum value
on the %CpG methylatyion axis (y) for the ALCAM-negative tumor cells MDA-MB-435 and FEMX1 are 75% and 100% respectively, and 10% for
cells with endogenous ALCAM expression.
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Page 8 of 16Figure 6 5-aza-deoxydytidine activates ALCAM expression in tumor cells. A) top panel; Histogram showing baseline methylation at each
CpG sites in the ALCAM promoter in MDA-MB-435 cells (blank columns) and the percent methylation following treatment with 5 μM 5-aza-
deoxycytidine (filled columns). Lower panel; Profile of DNA demethylation across the proximal ALCAM promoter achieved by treating MDA-MB-
435 cells with 5 μM 5-aza-deoxycytidine. B) Dose-dependent re-activation of ALCAM mRNA and protein expression in MDA-MB-435 cells treated
with a concentration range (0-10 μM) of 5-aza-deoxycytidine.
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Page 9 of 16suggests that ALCAM is a target of the NF-Bp a t h w a y .
Our data in melanoma cells is consistent with previous
reports showing that transformation of avian lymphoma
B-cells with v-rel induces ectopic expression of ALCAM
[32]. Mutations of cell cycle genes activate NF-B,
which in turn is directly responsible for increasing
expression of several target genes involved in melano-
gensis [33-36]. Given the marked elevation of expression
of ALCAM in vertically growing primary melanoma
tumors, it is likely that the ALCAM gene locus is a
downstream target of NF-B in melanoma. Our reporter
gene analysis did not reveal cis-active elements in the
ALCAM promoter that suppress ALCAM expression in
breast cancer cell lines. However, the human ALCAM
gene locus is relatively large [37] and may contain nega-
tive regulatory elements far upstream of the transcrip-
tion start site, where they may influence gene
expression, via long-range DNA looping.
Epigenetic modification of DNA is a well established
mechanism for suppressing genes, and we discovered
Figure 7 ALCAM clusters tumor cells circulating through the lung. A) Ectopic expression of ALCAM in MDA-MB-435 tumor cells. Left panel;
Western blot analysis of ALCAM in MDA-MB-435 clones transfected with an empty vector (lane 1) or, an ALCAM-GFP vector (lane 2). Protein
loading was verified by probing the same western blot filter for the house keeping protein EF1-a. Right panel; Monolayer of MDA-MB-435-
ALCAM-GFP cells were examined by live-cell microscopy to reveal expression of ALCAM at sites of cell-cell contact. B) Medium power image
show virtual absence of control MDA-MB-435 cells, except for a single cell (arrow) while the ALCAM-expressing MDA-MB-435 clones form
clusters (brown stain) after 90 minute perfusion in rat lungs. C) Number of tumor cells retained in rat lungs in experiments using ALCAM-positive
(n = 7), or ALCAM-negative MDA-MB-435 cells (n = 4) pre-treated with non-immune IgG or monoclonal anti-ALCAM antibody. D) Number of
tumor cell clusters retained in rat lungs in experiments using ALCAM-positive and ALCAM-negative MDA-MB-435 cells pre-treated with non-
immune IgG (n = 7) or monoclonal anti-ALCAM antibody (n = 7). E) Number of single tumor cells retained in rat lungs in experiments using
ALCAM-positive and ALCAM-negative MDA-MB-435 cells pre-treated with non-immune IgG (n = 7) or monoclonal anti-ALCAM antibody (n = 7).
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Page 10 of 16Figure 8 Anti-ALCAM antibodies reduce clustering of tumor cells circulating through the lung. A) (i) Medium power image of a rat lung
section show MDA-MB-231 tumor cells logged in a medium-size vessel, ii) magnified section of the area enclosed by the dotted box in (i). B)
Low-power image of rat lung section show MDA-MB-231 tumor cells in experiments with non-immune IgG (i) or anti-ALCAM antibody (ii). C)
Number of tumor cells retained in isolated perfused rat lungs following incubations with non-immune IgG (n = 11) and Novocastra (n = 4) and
GW (n = 7) monoclonal anti-ALCAM antibodies.
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multiple CpG islands, which are targets for DNA methy-
lation (Fig. 5A). Sequencing revealed that virtually all
CpG islands in the ALCAM promoter are methylated in
tumor cells lacking ALCAM expression. The plasticity
of this modification, and its inherent linkage to gene
expression was confirmed in experiments with 5-aza-
deoxycytidine (Fig. 6A, B). Additional correlative data in
both breast cancer and melanoma cell lines showed
direct relationship between the level of DNA methyla-
tion of the ALCAM promoter and ALCAM protein
level (Fig. 5B). 5-Aza-deoxycytidine is currently in clini-
cal use, and may be indicated to boost ALCAM expres-
sion in breast cancer [38], however, it also alters
expression of a large number of genes [39,40]. More-
over, our data suggests this drug alone maybe insuffi-
cient to fully restore ALCAM expression in tumors with
severely repressed ALCAM expression. The level of
ALCAM expression is variable in different tumor types.
This heterogeneity can be resolved by the unique tissue
origins of different tumors, although variable expres-
sions have been described at different stages of tumor
development in the same type of malignancies. With
respect to breast cancer, multiple studies have examined
ALCAM expression at the transcript and protein levels,
using a variety of methods. There is an emerging con-
sensus that low level ALCAM is a bad prognostic mar-
ker in breast cancer [23,24,27,41-44]. In the largest, and
most recent study, Ihnen et al found that low ALCAM
mRNA was associated with shorter disease free survival
and duration of survival in hierarchical cluster analysis
involving training and multiple validation cohorts of
breast cancer patients [44]. This emerging paradigm is
supported by the correlations of high ALCAM mRNA
with progesterone and estrogen receptor status, better
response and longer overall survival. It is reasonable to
presume that down-regulation of ALCAM activates
alternative compensatory pathways. Plausible candidates
are other ALCAM isoforms, such as soluble ALCAM,
which may account for the elevation of serum ALCAM
in patients with breast cancer [45]. A similar mechanism
may explain the marked increased in cytoplasmic
ALCAM in some aggressive breast cancer tissues [26].
While the relationships between these various deregula-
tions of ALCAM expression remain to be verified, they
all represent loss of function of ALCAM, which to date
has consistently been associated with poor prognosis in
breast cancer.
Alteration of adhesion molecule expression is a hall-
mark of several cancers [46], however the underlying
biological mechanism for the deleterious effects of
reduced ALCAM in breast cancer is poorly defined. In
this study, we examined the impact of ALCAM on the
adhesive behavior of tumor cells in the pulmonary
vasculature using the isolated rat lung system. Experi-
ments using two function blocking ALCAM antibodies,
and genetically-modified MDA-MB-435 clones ectopi-
cally expressing ALCAM, revealed that ALCAM pro-
motes homotypic tumor cell adhesion demonstrated by
clusters of tumor cells in the pulmonary vasculature.
ALCAM is localized at sites of lateral cell contacts in
the pulmonary endothelium, and is therefore unlikely to
mediate adhesions between circulating tumor cells and
the endothelium [47]. Colonization of the lung by
tumor cells involves their interaction with the endothe-
lial wall, and subsequent extravasations. The data
reported here suggests that ALCAM is likely to slow
down this process, by promoting homotypic tumor cell
adhesion. This idea is pertinent to the level of ALCAM
expression and the metastatic phenotypes of the two
tumor cells lines we used in our lung perfusion experi-
ments. The ALCAM-positive MDA-MB-231 cells which
formed large cell clusters in the rat lung cannot metas-
tasize to distant sites when injected into the mammary
fat pad of athymic nude mice [48,49]. On the contrary,
ALCAM-negative MDA-MB-435 efficiently and sponta-
neously forms distant metastasis under identical experi-
mental conditions [48-51]. Additional mechanistic
studies are needed to clearly define the relationship
between ALCAM level and the metastatic phenotypes of
tumor cells. In this study, we have shown that loss of
ALCAM function in MDA-MB-231 and gain of
ALCAM function in MDA-MB-435, switches their adhe-
sive phenotypes in the pulmonary vasculature, a process
that influences metastasis to the lung [30,31].
Conclusions
The ALCAM promoter is extensively methylated in
tumor cells that lack ALCAM expression. Using genetic
and antibody blocking assays we demonstrate that
ALCAM enhances homotypic adhesion of tumor cells
perfusing through the pulmonary vasculature. Thus,
reduced homotypic tumor cell adhesion may explain
why low-level ALCAM is a risk factor for metastasis
and early death in breast cancer. Therapeutic strategies
that re-activate ALCAM expression in breast cancer
tumors may slow-down tumor metastasis and improve
survival.
Methods
Cells
Cells studied included MDA-MB-435, originally classi-
fied as of breast cancer origin, but recently shown to
posses melanocytic lineage, fifteen breast cancer (BT549,
BT483, MDA-MB-231, HCC70, HCC1428, HCC1806,
MDA-MB-453, MCF-7, CAMA-1, MB-157, MDA-MB-
361, HCC1500, HCC1008, T47D and SK-BR-3) and two
normal epithelial breast cell lines (MCF-10A and MCF-
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Page 12 of 1612A) purchased from American Type Culture Collection
(ATCC, Rockville, MD). In addition, four melanoma cell
l i n e s( F E M X - I ,L O X ,M e l J u s o ,C 8 1 6 1 . 9 )w e r es t u d i e d .
All cell lines were cultured using media conditions
recommended by the commercial or academic suppliers.
Cells were incubated at 37°C in a humidified chamber
with 5% CO2 (except for MDA-MB-361, which was cul-
tured in room air). MDA-MB-435 cells (2 × 10
5 per 35-
mm well) were plated overnight, and then treated with a
concentration range (0-10 μM) of 5-aza-2-deoxycytidine
(EMD, Madison, WI). Cells were replenished with fresh
medium containing 5-aza-2-deoxycytidine every 48
hours for six days, and harvested for analysis.
Western Blots
Cell lysates (20 μg) were resolved on a 10% SDS-PAGE.
Proteins were transferred to PVDF membrane and
probed with antibodies (ALCAM/CD166, Novocastra
Laboratories) and secondary antibody conjugated to
horseradish peroxidase and detected using chemilumi-
nescence (Pierce Biotechnology; Rockford, IL).
Quantitative RT-PCR and 5’ RACE
Total RNA was extracted using RNeasy Mini Kit (Qia-
gen, Valencia, CA) and converted to cDNA from 2 μg
total RNA by SuperScript RT II (Invitrogen, Carlsbad,
CA). Quantitative RT-PCR was performed using an ABI
StepOnePlus analyzer (Applied Biosystems, Foster City,
CA) with SYBR Green master mixture containing pri-
mers for ALCAM (NM_001627) or GAPDH (Additional
file 1: Table S1). The start of RNA synthesis was identi-
fied using the rapid amplification of cDNA ends
(RACE) approach (5’RACE, Invitrogen). Briefly, ALCAM
cDNA was synthesized from 3 μgR N Au s i n gS u p e r -
Script RT II and ALCAM-specific primer AL1 (Addi-
tional file 1: Table S1), and purified using SNAP
column (Invitrogen), tailed with TdT and amplified by
PCR using abridged anchor primer (AAP) and ALCAM-
specific primer AL2. PCR product was amplified using a
nested ALCAM-specific primer AL3 and universal
amplification primer (UAP), cloned into a T-vector and
sequenced.
DNA constructs and stable cell lines
Human genomic DNA was amplified by PCR using a
common reverse primer and various forward primers
truncated at -2600, -1800, -1400, -1200, -1000, -800,
-650, -400 and -200 (Additional file 1: Table S1). PCR
products were cloned into a promoter-less luciferase
vector (pGL3, Promega, Madison, WI) via Mlu I and Bgl
II, and verified by DNA sequencing. We have previously
described construction of a fusion DNA vector expres-
sing ALCAM and enhanced green fluorescent protein
(GFP) [47]. ALCAM-GFP and control GFP vector
(Applied Vironomics, Fremont, CA) were transfected
into log-phase growing MDA-MB-435 cells using lipo-
fectamine 2000 (Invitrogen). Stable lines of MDA-MB-
435-ALCAM-GFP and MDA-MB-435-GFP were
selected using G418 (500 μg/ml).
Reporter assays
Cells (8 × 10
4) were seeded in 24-well tissue culture
plates and co-transfected with ALCAM promoter luci-
ferase plasmids (800 ng) and pcDNA3.1/His/LacZ (100
ng) (Invitrogen) plasmid DNA using lipofectamine 2000.
Twenty-four hours after transfection cell lysates were
prepared and the activities of luciferase (Firefly-Lucifer-
ase Reporter Assay System, Promega) and b-galactosi-
dase (Galacto-Star system, Applied Biosystems)
determined using the Veritas Luminometer (Turner Bio-
systems, Sunnyvale, CA). Luciferase activity was normal-
ized to the activity of b-galactosidase, and the relative
luciferase activity for test constructs calculated by
assigning the normalized luciferase activity of the pro-
moter-less pGL3 construct as 1.0. Minimum of three
independent experiments was performed for each repor-
ter each in triplicate.
Electrophoretic mobility shift assay
In vitro protein-DNA interaction was examined using
the LightShift Chemiluminescent electrophoretic mobi-
lity shift assay (EMSA) kit (Pierce). ALCAM-specific
EMSA DNA probes were synthesized, gel purified and
biotin labeled (Additional file 1: Table S1). Nuclear
extract (4 μg) was combined with biotin-labeled DNA
probes in binding buffer containing 50 μg/ml poly(dI-
dC). Fifty-fold molar excess of unlabelled DNA probe
was added to the binding reaction in competition
experiments. Anti-p65 NF-B antibodies (2 μg) (Santa
Cruz) were added to the reaction mixture. Products of
the binding reaction were resolved in 6% DNA retarda-
tion gel, transferred to a nylon membrane and biotin-
labeled complexes detected by chemiluminescence (Fuji-
film LAS-1000 imaging system; FujiFilm, Valhalla, NY).
Chromatin immunoprecipitation assay
Protein-DNA cross-linking was performed by fixing 40
million cells with 1% formaldehyde. Nuclei was soni-
cated on ice in shearing buffer (ChIP-IT; Active Motif,
Carlsbad, CA) to obtain chromatin fragments of 100-
1000 base pairs, which were pre-cleared with protein G
beads (Salmon sperm DNA/Protein G agarose). Pre-
cleared chromatin was incubated with anti-p65 NF-B
antibody (Santa Cruz) or non-immune IgG. Immune
complexes were precipitated with protein G beads, and
the eluate reversed cross-linked in 190 mM NaCl. DNA
was purified and amplified by PCR with specific
ALCAM primers (Additional file 1: Table S1).
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Genomic DNA was extracted using QIAamp DNA Mini
Kit (Qiagen) and 1 μg of this sample treated with
sodium bisulfite (EZ Methylation Gold kit, Zymo
Research, Orange, CA). Bisulfite-modified DNA (1 μl)
was amplified in two separate PCR reactions using pri-
mers flanking the interval -256 to -118 of the ALCAM
promoter and specific for methylated and unmethylated
genomic DNA (Additional file 1: Table S1). For bisulfite
sequencing biotinylated reverse primers were used in
two separate reactions to amplify two distinct and over-
lapping DNA fragments in the interval -409 to -62. Bio-
tin-labeled single-stranded PCR products were isolated
and pyrosequenced (PSQ™96HS System EpigenDx Bio-
tage, Kungsgatan, Sweden). Methylation status of each
CpG site was analyzed individually as T/C SNP using
QCpG software (Biotage, Kungsgatan, Sweden).
Isolated perfused lungs
T h ei s o l a t e dp e r f u s e dv e n t ilated rat lung was prepared
as we have described previously [52,53]. Adult male
Sprague-Dawley rats were anesthetized with pentobarbi-
tal sodium (60 mg/kg ip), and a catheter was inserted
into the trachea, and the lungs were mechanically venti-
lated. A median sternotomy was performed, and then
heparin (60 units) was administered via the left ventricle
and allowed to circulate for 3 min. Catheters were
placed and secured around the pulmonary artery and
the left atrium. Rat lungs were perfused with Earle’s
balanced salt solution and 4% bovine serum albumin
containing tumor cells at a density of 40,000 cells per
ml. In some experiments, tumor cells (2 × 10
6)w e r e
incubated for 1 hour with anti-ALCAM (1:20 Novocas-
tra or 1:20 GW, GenWay Bioetech) or non-immune IgG
(control) prior to perfusion. Tumor cells were perfused
for 90 minutes followed by perfusion with Earle’s
balanced salt solution without tumor cells for 5 minutes.
Immunostaining
Breast cancer cells were fixed with methanol and
blocked with 3% normal goat serum, followed by stain-
ing with 1/100 dilution of anti-ALCAM (Novocastra
Laboratories Ltd), and Alexflour 594 goat anti-rabbit
IgG (Molecular Probes, Eugene, Oregon). Nucleus was
stained with DAPI (Molecular Probe). Cells were
examined by epifluorescence (Nikon TE2000, Nikon
Instruments Inc., Melville, NY). Lung tissue was fixed
in 10% formalin or 4% paraformaldehyde, processed,
embedded in paraffin, and sectioned (4-5 microns).
Sections were stained with hematoxylin & eosin
(H&E), anti-GFP (1:250; Molecular Probes, Inc.,
E u g e n e ,O R ) ,o ra n t i - A L C A M( 1 : 4 0 ;N o v o c a s t r a
Laboratories Ltd). Tumor cells in twenty 40× fields
were counted on each section/slide. A total of forty
lung fields (40×) per rat lung were analyzed by light
microscopy to assess for tumor cells. The number of
tumor cells and presence of single cells or cell aggre-
gates were recorded. Sections were photographed with
a Nikon E600 light microscope with digital imaging
(Nikon Instruments Inc., Melville, NY).
Statistics
The data are reported as the means ± SE for at least
three independent experiments. Data was graphed and
analyzed using Prism software (GraphPad Software). Sta-
tistical analysis of the raw data was performed by two
tailed t tests. Differences were considered significant if p
value were < 0.05 (*), <0.01 (**) and <0.001 (***).
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